The drug safety technology platform in the cloud

PROHALO is a game-changing solution with a unique subscription model, that will revolutionize drug safety (pharmacovigilance) for pharma companies big and small. Its new features will transform the way that companies can manage their PV processes and promises to create a unified ‘Integrated Universe’ that all pharma companies can enjoy, regardless of their size. PROHALO is a significant development for Insife which launched HALOPV in 2018, first with a couple of modules, later on growing into the world’s first fully comprehensive and cohesive PV solution. Managing all multi-vigilance processes from operational to scientific, HALOPV allows companies to add on whichever of the 18 modules that they required specifically for their business, creating a bespoke platform for each customer. However, where HALOPV was developed initially with the top pharma companies in mind, Insife has been considering how the platform could be advanced so that it can be adopted by all companies, big and small, as well as CROs and Health Authorities worldwide. Key attributes had to be easier compliance, simple ways to exchange and share data and making the platform both fully integratable as well as scalable for companies as they grow. Finally, to allow smaller companies and markets to get the opportunity to use this technology, this new solution had to be affordable for all. The answer is PROHALO, the new PV ‘Integrated Universe’, where all companies can start using the platform at entry level for free. ‘No man is an island. This system will unify pharma. It will make it easy to not just operate on your own, but to operate with all the partners that you need across the world, and to do it simply and quickly on an affordable platform for all. That’s PROHALO!’ Martin Holm-Peterson, CEO, Insife